PortfoliosLab logoPortfoliosLab logo
Collegium Pharmaceutical, Inc. (COLL)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US19459J1043
CUSIP
19459J104
IPO Date
May 7, 2015

Highlights

Market Cap
$1.31B
Enterprise Value
$1.93B
EPS (TTM)
$1.60
PE Ratio
20.73
PEG Ratio
0.50
Total Revenue (TTM)
$780.57M
Gross Profit (TTM)
$463.26M
EBITDA (TTM)
$599.85M
Year Range
$23.23 - $50.79
Target Price
$58.00
ROA (TTM)
3.79%
ROE (TTM)
20.84%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Collegium Pharmaceutical, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Collegium Pharmaceutical, Inc. (COLL) has returned -28.57% so far this year and 10.79% over the past 12 months. Over the last ten years, COLL has returned 5.60% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


Collegium Pharmaceutical, Inc.

1D
3.38%
1M
-20.64%
YTD
-28.57%
6M
-5.49%
1Y
10.79%
3Y*
11.29%
5Y*
7.18%
10Y*
5.60%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since May 7, 2015, COLL's average daily return is +0.10%, while the average monthly return is +2.52%. At this rate, your investment would double in approximately 2.3 years.

Historically, 50% of months were positive and 50% were negative. The best month was Sep 2016 with a return of +131.2%, while the worst month was Jan 2016 at -38.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.

On a daily basis, COLL closed higher 49% of trading days. The best single day was Sep 14, 2015 with a return of +39.5%, while the worst single day was Jan 7, 2019 at -19.6%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-0.82%-9.26%-20.64%-28.57%
202512.11%-9.56%2.75%-9.56%7.95%1.48%0.98%29.94%-9.82%2.89%29.67%-0.81%61.61%
20247.08%11.38%5.75%-4.87%-10.26%-2.84%19.78%-0.29%0.47%-11.65%-10.66%-6.07%-6.92%
202321.03%-5.52%-9.57%-3.00%-5.16%-2.63%5.91%2.90%-4.57%-2.64%17.78%20.09%32.67%
2022-4.44%9.08%4.57%-20.92%-2.98%13.44%-2.99%2.27%-8.87%11.99%21.91%6.08%24.20%
202120.52%-2.28%0.47%-5.91%7.13%-1.05%5.29%-17.52%-3.85%-0.56%-10.44%6.26%-6.74%

Benchmark Metrics

Collegium Pharmaceutical, Inc. has an annualized alpha of 14.74%, beta of 0.97, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since May 08, 2015.

  • This stock participated in 79.89% of S&P 500 Index downside but only 77.04% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
14.74%
Beta
0.97
0.09
Upside Capture
77.04%
Downside Capture
79.89%

Return for Risk

Risk / Return Rank

COLL ranks 48 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.


COLL Risk / Return Rank: 4848
Overall Rank
COLL Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
COLL Sortino Ratio Rank: 4646
Sortino Ratio Rank
COLL Omega Ratio Rank: 4545
Omega Ratio Rank
COLL Calmar Ratio Rank: 4848
Calmar Ratio Rank
COLL Martin Ratio Rank: 5252
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Collegium Pharmaceutical, Inc. (COLL) and compare them to a chosen benchmark (S&P 500 Index).


COLLBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.28

0.90

-0.62

Sortino ratio

Return per unit of downside risk

0.70

1.39

-0.69

Omega ratio

Gain probability vs. loss probability

1.08

1.21

-0.13

Calmar ratio

Return relative to maximum drawdown

0.32

1.40

-1.08

Martin ratio

Return relative to average drawdown

1.02

6.61

-5.59

Explore COLL risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Collegium Pharmaceutical, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Collegium Pharmaceutical, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Collegium Pharmaceutical, Inc. was 73.59%, occurring on May 8, 2017. Recovery took 210 trading sessions.

The current Collegium Pharmaceutical, Inc. drawdown is 33.65%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-73.59%Dec 31, 2015340May 8, 2017210Mar 8, 2018550
-65.22%Mar 9, 2018344Jul 22, 2019890Feb 1, 20231234
-41.07%Oct 7, 2024128Apr 10, 2025146Nov 7, 2025274
-35.81%Dec 29, 202563Mar 30, 2026
-35.05%Aug 3, 201522Sep 1, 201510Sep 16, 201532

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Collegium Pharmaceutical, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Collegium Pharmaceutical, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for COLL, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, COLL has a P/E ratio of 20.7. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for COLL compared to other companies in the Drug Manufacturers - Specialty & Generic industry. COLL currently has a PEG ratio of 0.5. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for COLL relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, COLL has a P/S ratio of 1.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for COLL in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, COLL has a P/B value of 4.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items